Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac toxicity was assessed by simple incidence rates and rates per 100 person-years. Univariate and multivariate Cox regression was conducted. Results: Panitumumab-containing therapy significantly increased the risk of developing cardiac arrhythmias (p = 0.036), but not for any cardiac event (p = 0.24) or ischemic event (p = 0.087). The absolute rate of developing cardiac arrhythmia was 10.0 events versus 7.5 events per 100 person-years. Pre-existing hypertension (p = 0.033), history of cardiac disease (p = 0.055) or panitumumab usage (p = 0.046) were risk factors for cardiac arrhythmias. Conclusion: The addition of panitumumab to chemotherapy increases the risk of developing cardiac arrhythmia, but not for any cardiac toxicity or ischemic events.

Keywords:

References

1. Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives. Drugs 79(6), 633–645 (2019).
Medline CASGoogle Scholar
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358(11), 1160–1174 (2008).
Medline CASGoogle Scholar
3. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59(8), 1935–1940 (1999).
Medline CASGoogle Scholar
4. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3–S8 (2001).
Medline CASGoogle Scholar
5. Peng D, Fan Z, Lu Y, Deblasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56(16), 3666–3669 (1996).
Medline CASGoogle Scholar
6. Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr. Opin. Obstet. Gynecol. 23(1), 37–43 (2011).
MedlineGoogle Scholar
7. Vermorken JB, Stohlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label Phase III randomised trial. Lancet Oncol. 14(8), 697–710 (2013).
Medline CASGoogle Scholar
8. Degirmencioglu S, Tanriverdi O, Menekse S et al. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: a collaborative study by Turkish Oncology Group (TOG). J. BUON 24(1), 136–142 (2019).
MedlineGoogle Scholar
9. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label Phase III trial. Lancet Oncol. 14(6), 481–489 (2013).
Medline CASGoogle Scholar
10. Mauri G, Pizzutilo EG, Amatu A et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat. Rev. 73, 41–53 (2019).
Medline CASGoogle Scholar
11. Colucci G, Giuliani F, Garufi C et al. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter Phase II study. Oncology 79(5–6), 415–422 (2010).
Medline CASGoogle Scholar
12. Aranda E, Garcia-Alfonso P, Benavides M et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur. J. Cancer 101, 263–272 (2018).
Medline CASGoogle Scholar
13. Magrini SM, Buglione M, Corvo R et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized Phase II trial. J. Clin. Oncol. 34(5), 427–435 (2016).
Medline CASGoogle Scholar
14. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116–1127 (2008).
Medline CASGoogle Scholar
15. Ruhstaller T, Thuss-Patience P, Hayoz S et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, Phase III trial (SAKK 75/08). Ann. Oncol. 29(6), 1386–1393 (2018).
Medline CASGoogle Scholar
16. Peng L, Liu ZL, Xu C et al. The efficacy and safety of anti-epidermal growth factor receptor monoclonal antibodies in nasopharyngeal carcinoma: literature-based meta-analyses. J. Cancer 9(23), 4510–4520 (2018).
MedlineGoogle Scholar
17. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369(11), 1023–1034 (2013).
Medline CASGoogle Scholar
18. Poulin-Costello M, Azoulay L, Van Cutsem E, Peeters M, Siena S, Wolf M. An analysis of the treatment effect of panitumumab on overall survival from a Phase III, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target. Oncol. 8(2), 127–136 (2013).
MedlineGoogle Scholar
19. Qi WX, Fu S, Zhang Q, Guo XM. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med. 12, 203 (2014).
MedlineGoogle Scholar
20. Qi WX, Min DL, Shen Z et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int. J. Cancer 132(12), 2967–2974 (2013).
Medline CASGoogle Scholar
21. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials. J. Chemother. 26(6), 359–368 (2014).
Medline CASGoogle Scholar
22. Tang XM, Chen H, Liu Y et al. The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Medicine 96(3), e5946 (2017).
Medline CASGoogle Scholar
23. Xiao Y, Yin J, Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS ONE 9(1), e87671 (2014).
MedlineGoogle Scholar
24. Mouhayar E, Durand JB, Cortes J. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin. Drug Saf. 12(5), 687–696 (2013).
Medline CASGoogle Scholar
25. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 49(3), 287–297 (2010).
Medline CASGoogle Scholar
26. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 15(2), 130–141 (2010).
Medline CASGoogle Scholar
27. Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br. J. Clin. Pharmacol. 78(4), 748–762 (2014).
Medline CASGoogle Scholar
28. Crown JP, Dieras V, Staroslawska E et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J. Clin. Oncol. 31(23), 2870–2878 (2013).
Medline CASGoogle Scholar
29. Chaudhary P, Gajra A. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Cardiovasc. Hematol. Agents Med. Chem. 8(3), 156–163 (2010).
Medline CASGoogle Scholar
30. Tang XM, Chen H, Li Q et al. Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC. Onco Targets Ther. 11, 123–129 (2018).
MedlineGoogle Scholar
31. Project Data Sphere (2019). www.projectdatasphere.org/projectdatasphere/html/home
Google Scholar
32. Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672–680 (2009).
Medline CASGoogle Scholar
33. Peeters M, Oliner KS, Price TJ et al. Analysis of KRAS/NRAS mutations in a Phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin. Cancer Res. 21(24), 5469–5479 (2015).
Medline CASGoogle Scholar
34. Investigators OT, Gerstein HC, Bosch J et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367(4), 319–328 (2012).
MedlineGoogle Scholar
35. Singh I, Amin H, Rah B, Goswami A. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer. Front. Biosci. (Schol. Ed.) 5, 231–246 (2013).
MedlineGoogle Scholar
36. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol. Cancer 17(1), 53 (2018).
MedlineGoogle Scholar
37. Zhang B, Fang C, Deng D, Xia L. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol. Lett. 16(1), 27–33 (2018).
Medline CASGoogle Scholar
38. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697–4705 (2010).
Medline CASGoogle Scholar
39. Zhao YY, Sawyer DR, Baliga RR et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 273(17), 10261–10269 (1998).
Medline CASGoogle Scholar
40. Erickson SL, O’Shea KS, Ghaboosi N et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 124(24), 4999–5011 (1997).
Medline CASGoogle Scholar
41. Zhao YY, Feron O, Dessy C, Han X, Marchionni MA, Kelly RA. Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes. Circ. Res. 84(12), 1380–1387 (1999).
Medline CASGoogle Scholar
42. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5(2), 257–265 (1999).
Medline CASGoogle Scholar
43. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl Cancer Inst. 97(16), 1221–1224 (2005).
Medline CASGoogle Scholar
44. Thangarasa T, Gotfrit J, Goodwin RA et al. Epidermal growth factor receptor inhibitor-induced hypomagnesemia: a survey of practice patterns among Canadian gastrointestinal medical oncologists. Curr. Oncol. 26(2), e162–e166 (2019).
Medline CASGoogle Scholar
45. Hsieh MC, Wu CF, Chen CW, Shi CS, Huang WS, Kuan FC. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis. Sci. Rep. 8(1), 2047 (2018).
MedlineGoogle Scholar
46. Fakih M. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? Expert Rev. Anticancer Ther. 8(9), 1471–1480 (2008).
Medline CASGoogle Scholar
47. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin. Colorectal Cancer 6(2), 152–156 (2006).
Medline CASGoogle Scholar
48. Kim TW, Elme A, Kusic Z et al. A Phase III trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br. J. Cancer 115(10), 1206–1214 (2016).
Medline CASGoogle Scholar
49. Abdel-Rahman O. 5-fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer. Clin. Colorectal Cancer 18(1), 58–63 (2019).
MedlineGoogle Scholar
50. Des Guetz G, Uzzan B, Chouahnia K, Morere JF. Cardiovascular toxicity of anti-angiogenic drugs. Target. Oncol. 6(4), 197–202 (2011).
MedlineGoogle Scholar
51. Qi WX, Fu S, Zhang Q, Guo XM. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups. Clin. Drug Investig. 34(10), 681–690 (2014).
Medline CASGoogle Scholar

Vol. 16, No. 19

Supplemental Materials

Metrics

Downloaded 114 times

History

Received 19 January 2020

Accepted 23 April 2020

Published online 18 May 2020

Published in print July 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2020-0050

Disclaimer

This publication is based on research using information obtained from www.projectdatasphere.org, which is maintained by Project Data Sphere, LLC. Neither Project Data Sphere, LLC nor the owner(s) of any information from the website have contributed to, approved or are in any way responsible for the contents of this publication.

Financial & competing interests disclosure

This study was supported in part by the National Natural Science Foundation of China (grant numbers 81673102, 81602791 and 81803164). National Key Research and Development Program of China (grant number 2016YFC0105409), Youth Foundation of Shanghai Health and Family Planning Commission (grant number 20164Y0066), Clinical Research Plan of SHDC (grant number 16CR1037B), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (grant number 20171904), Shanghai Jiaotong University Translational Medicine Fund Support (grant number ZH2018QNA54), Special construction of integrated Chinese and Western medicine in general hospital (grant numbers ZHYY-ZXYJHZ X-2-201704 and ZHYY-ZXYJHZ X-2-201913). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of reseearch

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all participants included in the study.

Data sharing statement

The authors certify that this manuscript reports the secondary analysis of clinical trial data that have been shared with them, and that the use of this shared data is in accordance with the terms (if any) agreed upon their receipt. The source of this data is: www.projectdatasphere.org, which is maintained by Project Data Sphere, LLC. Neither Project Data Sphere, LLC nor the owner(s) of any information from the website have contributed to, approved or are in any way responsible for the contents of this publication.

PDF download